Background
Methods
Patient eligibility
Study design and treatment
Assessments
Statistical analyses
Results
Patients
Proposed biosimilar pegfilgrastim (APO-Peg) (N = 294) | US-licensed pegfilgrastim reference product (US-Neulasta®) (N = 148) | EU-approved pegfilgrastim reference product (EU-Neulasta®) (N = 147) | Total (N = 589) | |
---|---|---|---|---|
Demographic data | ||||
Female, n (%) | 294 (100) | 148 (100) | 147 (100) | 589 (100) |
Age (years) | ||||
Mean (SD) | 51.9 (10.0) | 51.4 (10.4) | 51.5 (10.2) | 51.7 (10.1) |
Median (min, max) | 52.0 (24.0, 75.0) | 52.0 (27.0, 80.0) | 53.0 (22.0, 77.0) | 52.0 (22.0, 80.0) |
Race, n (%) Caucasian | 294 (100.0) | 148 (100.0) | 147 (100.0) | 589 (100.0) |
Body weight (kg) | ||||
Mean (SD) | 73.88 (14.4) | 72.01 (14.1) | 72.61 (12.9) | 73.09 (14.0) |
Median (min, max) | 73.0 (40.0, 120.0) | 70.0 (40.0, 118.0) | 70.0 (48.0, 119.0) | 72.0 (40.0, 120.0) |
Body height (cm) | ||||
Mean (SD) | 162.5 (6.8) | 162.7 (6.6) | 162.6 (6.4) | 162.6 (6.6) |
Median (min, max) | 163.0 (140.0, 180.0) | 163.0 (142.0, 180.0) | 163.0 (148.0, 183.0) | 163.0 (140.0, 183.0) |
Breast cancer history | ||||
Tumor parameter | ||||
Staging IIA | 129 (43.9) | 59 (39.9) | 58 (39.5) | 246 (41.8) |
Staging IIB | 79 (26.9) | 40 (27.0) | 44 (29.9) | 163 (27.7) |
Staging IIIA | 86 (29.3) | 49 (33.1) | 45 (30.6) | 180 (30.6) |
Comparative efficacy
Analysis Set Statistic | Proposed biosimilar pegfilgrastim (APO-Peg) | US-licensed pegfilgrastim reference product (US-Neulasta®) | EU-approved pegfilgrastim reference product (EU-Neulasta®) | (APO-Peg)-minus (US-Neulasta®) | (APO-Peg)-minus (EU-Neulasta®) | (EU-Neulasta®) minus (US-Neulasta®) |
---|---|---|---|---|---|---|
FAS (As Randomized) | ||||||
N | 294 | 148 | 147 | N/A | N/A | N/A |
LS Mean in days | 1.6 | 1.4 | 1.6 | 0.2 | 0.02 | 0.2 |
Median (Min, Max) in days | 2.0 (0, 10) | 1.0 (0, 5) | 2.0 (0, 10) | N/A | N/A | N/A |
95% CI in days | 1.47 to 1.79 | 1.17 to 1.61 | 1.38 to 1.83 | − 0.03 to 0.51 | − 0.25 to 0.30 | − 0.10 to 0.53 |
FAS (As Treated) | ||||||
N |
298
|
147
|
144
| N/A | N/A | N/A |
LS Mean in days | 1.6 | 1.4 | 1.6 | 0.2 | -0.01 | 0.2 |
Median (Min, Max) in days | 1.5 (0, 10) | 1.0 (0, 5) | 2.0 (0, 10) | N/A | N/A | N/A |
95% CI in days | 1.46 to 1.77 | 1.17 to 1.61 | 1.41 to 1.86 | − 0.04 to 0.50 | − 0.29 to 0.26 | − 0.07 to 0.56 |
Cycle | Proposed biosimilar pegfilgrastim (APO-Peg) | US-licensed pegfilgrastim reference product (US-Neulasta®) | EU-approved pegfilgrastim reference product (EU-Neulasta®) | Total |
---|---|---|---|---|
Cycle 1 | ||||
n/N (%) | 15/294 (5.1) | 6/148 (4.1) | 5/147 (3.4) | 26/589 (4.4) |
95% CI | 2.9–8.3 | 1.5–8.6 | 1.1–7.8 | 2.9–6.4 |
Cycle 2 | ||||
n/N (%) | 0/288 (0.0) | 1/146 (0.7) | 0/144 (0.0) | 1/578 (0.2) |
95% CI | 0.0–1.3 | 0.0–3.8 | 0.0–2.5 | 0.0–1.0 |
Cycle 3 | ||||
n/N (%) | 0/285 (0.0) | 0/146 (0.0) | 1/144 (0.7) | 1/575 (0.2) |
95% CI | 0.0–1.3 | 0.0–2.5 | 0.0–3.8 | 0.0–1.0 |
Cycle 4 | ||||
n/N (%) | 0/284 (0.0) | 0/144 (0.0) | 0/144 (0.0) | 0/572 (0.0) |
95% CI | 0.0–1.3 | 0.0–2.5 | 0.0–2.5 | 0.0–0.6 |
Cycle 5 | ||||
n/N (%) | 2/276 (0.7) | 0/143 (0.0) | 0/142 (0.0) | 2/561 (0.4) |
95% CI | 0.1–2.6 | 0.0–2.5 | 0.0–2.6 | 0.0–1.3 |
Cycle 6 | ||||
n/N (%) | 0/270 (0.0) | 0/143 (0.0) | 0/139 (0.0) | 0/552 (0.0) |
95% CI | 0.0–1.4 | 0.0–2.5 | 0.0–2.6 | 0.0–0.7 |
Overall | ||||
n/N (%) | 17/294 (5.8) | 7/148 (4.7) | 5/147 (3.4) | 29/589 (4.9) |
95% CI | 3.4–9.1 | 1.9–9.5 | 1.1–7.8 | 3.3–7.0 |
Characteristics | Proposed biosimilar pegfilgrastim (APO-Peg) N = 294 | US-licensed pegfilgrastim reference product (US-Neulasta®) N = 148 | EU-approved pegfilgrastim reference product (EU-Neulasta®) N = 147 | Total N = 589 |
---|---|---|---|---|
FAS-As Randomized | ||||
Day on which the peak ANC value was reached | ||||
N | 294 | 148 | 147 | 589 |
Mean (SD) | 3.4 (2.3) | 3.1 (0.6) | 3.1 (1.4) | 3.2 (1.8) |
Median | 3.0 | 3.0 | 3.0 | 3.0 |
Minimum–maximum | 1–24 | 3–9 | 1–18 | 1–24 |
95% CIs of mean | 3.1–3.6 | 3.0–3.2 | 2.9–3.4 | 3.1–3.4 |
Peak ANC value (× 109/L) | ||||
N | 294 | 148 | 147 | 589 |
Mean (SD) | 28.4 (9.5) | 29.9 (10.2) | 28.7 (9.3) | 28.9 (9.6) |
Median | 27.7 | 29.4 | 27.9 | 28.0 |
Minimum–maximum | 3.9–60.5 | 11.3–88.0 | 5.8–55.9 | 3.9–88.0 |
95% CIs of mean | 27.3–29.5 | 28.3–31.6 | 27.2–30.2 | 28.1–29.7 |
Day on which the depth of ANC nadir was reached | ||||
N | 294 | 148 | 147 | 589 |
Mean (SD) | 7.1 (1.8) | 7.1 (0.6) | 7.3 (2.1) | 7.1 (1.7) |
Median | 7.0 | 7.0 | 7.0 | 7.0 |
Minimum–maximum | 1–21 | 6–11 | 6–21 | 1–21 |
95% CIs of mean | 6.9–7.3 | 7.0–7.2 | 7.0–7.7 | 7.0–7.3 |
Depth of ANC nadir (× 109/L) | ||||
N | 294 | 148 | 147 | 589 |
Mean (SD) | 0.6 (1.1) | 0.4 (0.6) | 0.4 (0.7) | 0.5 (0.9) |
Median | 0.2 | 0.2 | 0.1 | 0.2 |
Minimum–maximum | 0.0–9.8 | 0.0–3.4 | 0.0–6.0 | 0.0–9.8 |
95% CIs of mean | 0.4–0.7 | 0.3–0.5 | 0.3–0.5 | 0.4–0.6 |
Day on which recovery of ANC was reached | ||||
N | 267 | 136 | 137 | 540 |
Mean (SD) | 9.4 (2.0) | 9.5 (2.1) | 9.2 (1.0) | 9.4 (1.8) |
Median | 9.0 | 9.0 | 9.0 | 9.0 |
Minimum–maximum | 6–25 | 8–22 | 8–13 | 6–25 |
95% CIs of mean | 9.2–9.7 | 9.1–9.8 | 9.0–9.4 | 9.2–9.5 |
Characteristics | Proposed biosimilar pegfilgrastim (APO-Peg) N = 298 | US-licensed pegfilgrastim reference product (US-Neulasta®) N = 147 | EU-approved pegfilgrastim reference product (EU-Neulasta®) N = 147 | Total N = 589 |
---|---|---|---|---|
FAS-As Treated | ||||
Day on which the peak ANC value was reached | ||||
N | 298 | 147 | 144 | 589 |
Mean (SD) | 3.4 (2.3) | 3.1 (0.5) | 3.1 (1.4) | 3.2 (1.8) |
Median | 3.0 | 3.0 | 3.0 | 3.0 |
Minimum–maximum | 1–24 | 3–9 | 1–18 | 1–24 |
95% CIs of mean | 3.1–3.6 | 3.0–3.2 | 2.9–3.4 | 3.1–3.4 |
Peak ANC value (× 109/L) | ||||
N | 298 | 147 | 144 | 589 |
Mean (SD) | 28.5 (9.6) | 29.7 (10.2) | 28.8 (9.2) | 28.9 (9.6) |
Median | 27.7 | 28.6 | 28.3 | 28.0 |
Minimum–maximum | 3.9–60.5 | 11.3–88.0 | 5.8–55.9 | 3.9–88.0 |
95% CIs of mean | 27.4–29.6 | 28.1–31.4 | 27.3–30.4 | 28.1–29.7 |
Day on which the depth of ANC nadir was reached | ||||
N | 298 | 147 | 144 | 589 |
Mean (SD) | 7.1 (2.0) | 7.1 (0.6) | 7.2 (1.8) | 7.1 (1.7) |
Median | 7.0 | 7.0 | 7.0 | 7.0 |
Minimum–maximum | 1–21 | 6–11 | 6–21 | 1–21 |
95% CIs of mean | 6.9–7.4 | 7.0–7.2 | 6.9–7.5 | 7.0–7.3 |
Depth of ANC nadir (× 109/L) | ||||
N | 298 | 147 | 144 | 589 |
Mean (SD) | 0.6 (1.1) | 0.4 (0.6) | 0.4 (0.7) | 0.5 (0.9) |
Median | 0.2 | 0.2 | 0.1 | 0.2 |
Minimum–maximum | 0.0–9.8 | 0.0–3.4 | 0.0–6.0 | 0.0–9.8 |
95% CIs of mean | 0.4–0.7 | 0.3–0.5 | 0.3–0.5 | 0.4–0.6 |
Day on which recovery of ANC was reached | ||||
N | 270 | 135 | 135 | 540 |
Mean (SD) | 9.4 (2) | 9.4 (2.1) | 9.2 (1.0) | 9.4 (1.8) |
Median | 9.0 | 9.0 | 9.0 | 9.0 |
Minimum–maximum | 6–25 | 8–22 | 8–13 | 6–25 |
95% CIs of mean | 9.2–9.7 | 9.1–9.8 | 9.0–9.4 | 9.2–9.5 |
Comparative safety
System organ class | Preferred term | Proposed biosimilar pegfilgrastim (APO-Peg) N = 329 | US-licensed pegfilgrastim reference product (US-Neulasta®) N = 135 | EU-approved pegfilgrastim reference product (EU-Neulasta®) N = 125 | Total N = 589 |
---|---|---|---|---|---|
Any AE | 295 (89.7) | 128 (94.8) | 116 (92.8) | 539 (91.5) | |
Blood and lymphatic system disorders | All PTs | 185 (56.2) | 88 (65.2) | 73 (58.4) | 346 (58.7) |
Anaemia | 14 (4.3) | 8 (5.9) | 8 (6.4) | 30 (5.1) | |
Febrile Neutropenia | 15 (4.6) | 7 (5.2) | 4 (3.2) | 26 (4.4) | |
Leukocytosis | 22 (6.7) | 17 (12.6) | 13 (10.4) | 52 (8.8) | |
Leukopenia | 63 (19.1) | 40 (29.6) | 41 (32.8) | 144 (24.4) | |
Neutropenia | 169 (51.4) | 79 (58.5) | 63 (50.4) | 311 (52.8) | |
Neutrophilia | 14 (4.3) | 13 (9.6) | 11 (8.8) | 38 (6.5) | |
Thrombocytopenia | 12 (3.6) | 5 (3.7) | 16 (12.8) | 33 (5.6) | |
Ear and labyrinth disorders | All PTs | 17 (5.2) | 11 (8.1) | 15 (12.0) | 43 (7.3) |
Vertigo | 17 (5.2) | 9 (6.7) | 14 (11.2) | 40 (6.8) | |
Gastrointestinal disorders | All PTs | 176 (53.5) | 81 (60.0) | 79 (63.2) | 336 (57.0) |
Abdominal pain | 19 (5.8) | 8 (5.9) | 11 (8.8) | 38 (6.5) | |
Abdominal pain Upper | 20 (6.1) | 12 (8.9) | 17 (13.6) | 49 (8.3) | |
Constipation | 8 (2.4) | 5 (3.7) | 7 (5.6) | 20 (3.4) | |
Diarrhoea | 54 (16.4) | 32 (23.7) | 34 (27.2) | 120 (20.4) | |
Dyspepsia | 9 (2.7) | 8 (5.9) | 11 (8.8) | 28 (4.8) | |
Nausea | 145 (44.1) | 67 (49.6) | 65 (52.0) | 277 (47.0) | |
Stomatitis | 20 (6.1) | 10 (7.4) | 5 (4.0) | 35 (5.9) | |
Vomiting | 44 (13.4) | 18 (13.3) | 27 (21.6) | 89 (15.1) | |
General disorders and administration site conditions | All PTs | 147 (44.7) | 71 (52.6) | 69 (55.2) | 287 (48.7) |
Asthenia | 81 (24.6) | 41 (30.4) | 31 (24.8) | 153 (26.0) | |
Fatigue | 43 (13.1) | 18 (13.3) | 32 (25.6) | 93 (15.8) | |
Malaise | 9 (2.7) | 8 (5.9) | 5 (4.0) | 22 (3.7) | |
Oedema Peripheral | 15 (4.6) | 10 (7.4) | 9 (7.2) | 34 (5.8) | |
Pyrexia | 22 (6.7) | 12 (8.9) | 18 (14.4) | 52 (8.8) | |
Metabolism and nutrition disorders | All PTs | 28 (8.5) | 16 (11.9) | 26 (20.8) | 70 (11.9) |
Decreased Appetite | 12 (3.6) | 9 (6.7) | 17 (13.6) | 38 (6.5) | |
Musculoskeletal and connective tissue disorders | All PTs | 166 (50.5) | 77 (57.0) | 80 (64.0) | 323 (54.8) |
Arthralgia | 13 (4.0) | 8 (5.9) | 10 (8.0) | 31 (5.3) | |
Bone pain | 149 (45.3) | 71 (52.6) | 70 (56.0) | 290 (49.2) | |
Myalgia | 28 (8.5) | 19 (14.1) | 15 (12.0) | 62 (10.5) | |
Nervous system disorders | All PTs | 119 (36.2) | 63 (46.7) | 53 (42.4) | 235 (39.9) |
Dizziness | 68 (20.7) | 24 (17.8) | 21 (16.8) | 113 (19.2) | |
Headache | 67 (20.4) | 38 (28.1) | 31 (24.8) | 136 (23.1) | |
Hypoesthesia | 9 (2.7) | 9 (6.7) | 6 (4.8) | 24 (4.1) | |
Respiratory, thoracic and mediastinal disorders | All PTs | 31 (9.4) | 16 (11.9) | 19 (15.2) | 66 (11.2) |
Oropharyngeal Pain | 14 (4.3) | 8 (5.9) | 6 (4.8) | 28 (4.8) | |
Skin and subcutaneous tissue disorders | All PTs | 92 (28.0) | 45 (33.3) | 46 (36.8) | 183 (31.1) |
Alopecia | 78 (23.7) | 36 (26.7) | 37 (29.6) | 151 (25.6) | |
Scar pain | 3 (0.9) | 0 (0.0) | 7 (5.6) | 10 (1.7) |